The patient clearly needs to be on an anticoagulant for stroke prevention with atrial fibrillation and I would choose apixaban. If an antiplatelet is added to the apixaban, the risk of a major bleeding side effect is significantly increased. It is uncertain if apixaban is effective in reducing the r...

Until atrial fibrillation is hopefully managed by conversion, the patient will be on an anticoagulant (apixaban) if the CHADS2 score dictates that. I would also add ASA 81 mg in cases of small vessel disease. If conversion is not feasible, medical management is determined on a case-by-case basis, bu...

Respectfully, I think this approach should require evidence-based justification regarding the following: That cardioversion of AF obviates the need for anticoagulation in patients with a history of stroke.  That adding ASA to anticoagulation in patients with AF and ICAD or small vessel dise...